1-6 of 6
Bradley Wubbenhorst
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer

Adam A. Kraya, Kara N. Maxwell, Bradley Wubbenhorst, Brandon M. Wenz, John Pluta, Andrew J. Rech, Liza M. Dorfman, Nicole Lunceford, Amanda Barrett, Nandita Mitra, Jennifer J.D. Morrissette, Michael Feldman, Anupma Nayak, Susan M. Domchek, Robert H. Vonderheide, Katherine L. Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4363–4374.
https://doi.org/10.1158/1078-0432.CCR-18-0468
Published: 15 July 2019
View articletitled, Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer
Open the PDF for Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma

Gao Zhang, Lawrence W. Wu, Ilgen Mender, Michal Barzily-Rokni, Marc R. Hammond, Omotayo Ope, Chaoran Cheng, Themistoklis Vasilopoulos, Sergio Randell, Norah Sadek, Aurelie Beroard, Min Xiao, Tian Tian, Jiufeng Tan, Umar Saeed, Eric Sugarman, Clemens Krepler, Patricia Brafford, Katrin Sproesser, Sengottuvelan Murugan, Rajasekharan Somasundaram, Bradley Garman, Bradley Wubbenhorst, Jonathan Woo, Xiangfan Yin, Qin Liu, Dennie T. Frederick, Benchun Miao, Wei Xu, Giorgos C. Karakousis, Xiaowei Xu, Lynn M. Schuchter, Tara C. Mitchell, Lawrence N. Kwong, Ravi K. Amaravadi, Yiling Lu, Genevieve M. Boland, Zhi Wei, Katherine Nathanson, Utz Herbig, Gordon B. Mills, Keith T. Flaherty, Meenhard Herlyn, Jerry W. Shay
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4771–4784.
https://doi.org/10.1158/1078-0432.CCR-17-2773
Published: 01 October 2018
View articletitled, Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Open the PDF for Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma in another window
Includes: Multimedia, Supplementary data
Journal Articles

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

Melissa A. Wilson, Fengmin Zhao, Sanika Khare, Jason Roszik, Scott E. Woodman, Kurt D'Andrea, Bradley Wubbenhorst, David L. Rimm, John M. Kirkwood, Harriet M. Kluger, Lynn M. Schuchter, Sandra J. Lee, Keith T. Flaherty, Katherine L. Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 374–382.
https://doi.org/10.1158/1078-0432.CCR-15-1162
Published: 14 January 2016
View articletitled, Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Open the PDF for Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma in another window
Includes: Supplementary data
Journal Articles

Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target

Guo Chen, Nitin Chakravarti, Kimberly Aardalen, Alexander J. Lazar, Michael T. Tetzlaff, Bradley Wubbenhorst, Sang-Bae Kim, Scott Kopetz, Alicia A. Ledoux, Y.N. Vashisht Gopal, Cristiano Goncalves Pereira, Wanleng Deng, Ju-Seog Lee, Katherine L. Nathanson, Kenneth D. Aldape, Victor G. Prieto, Darrin Stuart, Michael A. Davies
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (21): 5537–5546.
https://doi.org/10.1158/1078-0432.CCR-13-3003
Published: 30 October 2014
View articletitled, Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target
Open the PDF for Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target in another window
Includes: Supplementary data
Journal Articles

Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

Katherine L. Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, Joel Greshock, Richard Letrero, Kurt D'Andrea, Steven O'Day, Jeffrey R. Infante, Gerald S. Falchook, Hendrik-Tobias Arkenau, Michael Millward, Michael P. Brown, Anna Pavlick, Michael A. Davies, Bo Ma, Robert Gagnon, Martin Curtis, Peter F. Lebowitz, Richard Kefford, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4868–4878.
https://doi.org/10.1158/1078-0432.CCR-13-0827
Published: 02 September 2013
View articletitled, Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Open the PDF for Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) in another window
Includes: Supplementary data
Journal Articles

Abstract B12: PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas

Clemens Krepler, Meenhard Herlyn, Jessie Villanueva, Ahmed Samatar, Yuhao Chen, Molly Halloran, Minu Samanta, Xu He, Adina Vultur, Bradley Wubbenhorst, Katherine Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): B12.
https://doi.org/10.1158/1078-0432.MECHRES-B12
Published: 04 March 2013
View articletitled, Abstract B12: PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas
Open the PDF for Abstract B12: PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas in another window